We are live on
!
Find out more
FLSM
Frazier Life Sciences Management Portfolio holdings
AUM
$3.89B
1-Year Est. Return
201.1%
This Fund
S&P 500
This Quarter
Est. Return
+2.26%
1 Year Est. Return
+201.1%
3 Year Est. Return
+879.31%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.19B
AUM Growth
-$221M
(-9.2%)
Cap. Flow
-$84.5M
Cap. Flow
% of AUM
-3.86%
Top 10 Holdings %
Top 10 Hldgs %
70.17%
Holding
54
New
4
Increased
10
Reduced
8
Closed
7
Top Buys
| 1 |
MAZE
Maze Therapeutics
MAZE
|
+$49.7M |
| 2 |
Dyne Therapeutics
DYN
|
+$20.6M |
| 3 |
RNAM
Avidity Biosciences
RNAM
|
+$16.4M |
| 4 |
Zai Lab
ZLAB
|
+$10.8M |
| 5 |
Mirum Pharmaceuticals
MIRM
|
+$10.6M |
Top Sells
| 1 |
Rhythm Pharmaceuticals
RYTM
|
+$66.1M |
| 2 |
Edgewise Therapeutics
EWTX
|
+$33.9M |
| 3 |
Oric Pharmaceuticals
ORIC
|
+$21.7M |
| 4 |
AnaptysBio
ANAB
|
+$20.8M |
| 5 |
Krystal Biotech
KRYS
|
+$16.8M |
Sector Composition
| 1 | Healthcare | 99.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
NewAmsterdam Pharma
NAMS
$3.63B
| $330M | 15.08% |
16,116,418
+200,000
| +1% | +$4.45M |
|
|
2
Mirum Pharmaceuticals
MIRM
$7.16B
| $306M | 13.99% |
6,795,121
+224,729
| +3% | +$10.6M |
|
|
VRNA
3
DELISTED
Verona Pharma
VRNA
| $220M | 10.03% |
3,457,850
+73,900
| +2% | +$4.42M |
|
4
Arcutis Biotherapeutics
ARQT
$3.47B
| $137M | 6.28% |
8,785,284
| – | – |
|
5
BridgeBio Pharma
BBIO
$15.7B
| $131M | 6% |
3,800,457
| – | – |
|
|
6
Krystal Biotech
KRYS
$10.1B
| $124M | 5.67% |
688,460
-100,000
| -13% | -$16.8M |
|
7
Disc Medicine
IRON
$2.81B
| $87.1M | 3.98% |
1,754,834
| – | – |
|
8
Tarsus Pharmaceuticals
TARS
$2.52B
| $71.8M | 3.28% |
1,397,527
-190,000
| -12% | -$9.39M |
|
9
Trevi Therapeutics
TRVI
$2.46B
| $64.5M | 2.95% |
10,259,409
-405,365
| -4% | -$1.93M |
|
10
Phathom Pharmaceuticals
PHAT
$875M
| $63.4M | 2.9% |
10,109,279
| – | – |
|
|
KALV
11
DELISTED
KalVista Pharmaceuticals
KALV
| $56.4M | 2.58% |
4,887,867
| – | – |
|
|
MAZE
12
Maze Therapeutics
MAZE
$1.5B
| $45.5M | 2.08% |
+4,129,001
| New | +$49.7M |
|
|
MBX
13
MBX Biosciences
MBX
$2.78B
| $44.2M | 2.02% |
5,985,347
| – | – |
|
|
14
Rhythm Pharmaceuticals
RYTM
$7.28B
| $36M | 1.64% |
678,760
-1,191,048
| -64% | -$66.1M |
|
|
SLNO
15
DELISTED
Soleno Therapeutics
SLNO
| $35.7M | 1.63% |
499,159
-200,000
| -29% | -$9.74M |
|
16
Revolution Medicines
RVMD
$38.1B
| $35.3M | 1.61% |
997,455
| – | – |
|
17
Savara
SVRA
$1.13B
| $31.8M | 1.45% |
11,462,301
+2,801,922
| +32% | +$7.74M |
|
18
Agios Pharmaceuticals
AGIO
$2.3B
| $31.3M | 1.43% |
1,069,854
+100
| +0% | +$3.32K |
|
19
Erasca
ERAS
$5.91B
| $30.9M | 1.41% |
22,575,851
+3,184,164
| +16% | +$5.46M |
|
20
Ultragenyx Pharmaceutical
RARE
$2.98B
| $23.9M | 1.09% |
658,715
| – | – |
|
21
Ascendis Pharma A/S
ASND
$17B
| $20.8M | 0.95% |
133,333
| – | – |
|
22
Vaxcyte
PCVX
$8.09B
| $20.4M | 0.93% |
539,405
| – | – |
|
23
Alkermes
ALKS
$8.66B
| $19.8M | 0.91% |
601,129
| – | – |
|
|
PVLA
24
Palvella Therapeutics
PVLA
$2.12B
| $19.3M | 0.88% |
690,012
+36,120
| +6% | +$696K |
|
25
CG Oncology
CGON
$6.13B
| $18.9M | 0.86% |
770,000
| – | – |
|
Similar funds
GAMH
MSI
CCM
TFM
SCM
MIM
AA
DACG